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ABSTRACT
Introduction: Atopic dermatitis (AD) is an
inflammatory skin disease with a chronic,
relapsing course. Clinical features of AD vary by
age, duration, and severity but can include
papules, vesicles, erythema, exudate, xerosis,
scaling, and lichenification. However, the most
defining and universal symptom of AD is pru-
ritus. Pruritus or itch, defined as an unpleasant
urge to scratch, is problematic for many rea-
sons, particularly its negative impact on quality
of life. Despite the profoundly negative impact
of pruritus on patients with AD, clinicians and
researchers lack standardized and validated
methods to objectively measure pruritus. The
purpose of this review is to discuss emerging
methods to assess pruritus in AD by describing
objective patient-centered tools developed or
enhanced over the last decade that can be uti-
lized by clinicians and researchers alike.
Methods: This review is based on a literature
search in Medline, Embase, and Web of Science
databases. The search was performed in Febru-
ary 2019. The keywords were used ‘‘pruritus,’’
‘‘itch,’’ ‘‘atopic dermatitis,’’ ‘‘eczema,’’ ‘‘mea-
surements,’’ ‘‘tools,’’ ‘‘instruments,’’ ‘‘ac-
celerometer,’’ ‘‘wrist actigraphy,’’ ‘‘smartwatch,’’
‘‘transducer,’’ ‘‘vibration,’’ ‘‘brain mapping,’’
‘‘magnetic resonance imaging,’’ and ‘‘positron
emission tomography.’’ Only articles written in
English were included, and no restrictions were
set on study type. To focus on emerging meth-
ods, prioritization was given to results from the
last decade (2009–2019).
Results: The search yielded 49 results in
PubMed, 134 results in Embase, and 85 results
in Web of Science. Each result was indepen-
dently reviewed in a standardized manner by
two of the authors (M.S., K.L.), and disagree-
ments between reviewers were resolved by
consensus. Relevant findings were categorized
into the following sections: video surveillance,
acoustic surveillance, wrist actigraphy, smart
devices, vibration transducers, and neurological
imaging. Examples are provided along with
descriptions of how each technology works,
instances of use in research or clinical practice,
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and as applicable, reports of validation studies
and correlation with other methods.
Conclusion: The variety of new and improved
methods to evaluate pruritus in AD is welcomed
by clinicians, researchers, and patients alike.
Future directions include next-generation smart
devices as well as exploring new territories, such
as identifying biomarkers that correlate to itch
and machine-learning programs to identify itch
processing in the brain. As these efforts con-
tinue, it will be essential to remain patient-
centered by developing techniques that mini-
mize discomfort, respect privacy, and provide
accurate data that can be used to better manage
itch in AD.
Keywords: Atopic dermatitis; Diagnosis;
Eczema; Itch; Pruritus
INTRODUCTION
Atopic dermatitis (AD) is an inflammatory skin
disease with a chronic, relapsing course. Clini-
cal features of AD vary by age, duration, and
severity but can include papules, vesicles, ery-
thema, exudate, xerosis, scaling, and lichenifi-
cation. However, the most defining and
universal symptom of AD is pruritus. Pruritus or
itch, defined as an unpleasant urge to scratch, is
problematic for many reasons, particularly its
negative impact on quality of life. In fact, pru-
ritus in AD can be so severe and unrelenting
that it contributes to mental health conse-
quences ranging from hyperactivity [1, 2] to
generalized anxiety and even major depressive
disorders [3–5] in some patients.
Despite the profoundly negative impact of
pruritus on patients with AD, clinicians and
researchers lack standardized and validated
methods to objectively measure pruritus [6].
Since pruritus is an internalized sensation,
assessment typically hinges on subjective
patient reporting. A variety of scales and ques-
tionnaires have been developed for this pur-
pose. One of the most commonly used is the
Peak Pruritus Numerical Rating Scale (NRS),
which consists of a single question for the
patient: ‘‘On a scale of 0–10, with 0 being ‘no
itch’ and 10 being ‘worst itch imaginable,’ how
would you rate your itch at the worst moment
during the previous 24 h?’’ The Peak Pruritus
NRS was recently reported to be a well-defined,
reliable, sensitive, and valid scale for evaluating
worst itch intensity [7], and its efficient and
simple format makes it particularly attractive to
busy clinicians.
While such tools can be very useful in clini-
cal practice, patient-reported assessments are
less useful for research since biases arise from
differences in how an individual experiences
and describes pruritus. A ‘‘10 out of 10’’ or
‘‘worst itch imaginable’’ for one person might be
sensed much less severely by another person.
For example, a patient with years of chronic itch
may experience neural sensitization or desensi-
tization that can skew their self-reporting
[8–13]. Similarly, ‘‘itchy’’ is a common way to
describe pruritus, but some individuals may
experience it as a ‘‘burning’’ or a ‘‘tingling’’
sensation, potentially resulting in their pruritus
being inadequately captured by certain clinical
tools.
As these examples show, scales and ques-
tionnaires might be helpful for a clinician
treating an individual patient with AD, but
complementary and more objective tools are
needed to rigorously research this condition,
such as detecting subtle variations and com-
paring cohorts before and after an AD treatment
or intervention [14, 15]. The purpose of this
review is to discuss emerging methods to assess
pruritus in AD by describing objective patient-
centered tools developed or enhanced over the
last decade that can be utilized by clinicians and
researchers alike. Examples are provided along
with descriptions of how each technology
works, instances of use in research or clinical
practice, and as applicable, reports of validation
studies and correlation with other methods to
measure pruritus. Several of these methods
measure pruritus indirectly by quantifying
scratch, but several new technologies provide
novel ways to measure pruritus directly and
objectively. Given the centrality of pruritus in
AD, there is a need for more tools that allow
clinicians and researchers to accurately measure
this symptom in individual patients as well as
cohorts with AD.
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METHODS
This review is based on a literature search in
Medline, Embase, and Web of Science data-
bases. The search was performed in February
2019. The following primary keywords were
used: ‘‘pruritus,’’ ‘‘itch,’’ ‘‘atopic dermatitis,’’
‘‘eczema,’’ ‘‘measurements,’’ ‘‘tools,’’ and ‘‘in-
struments.’’ Preliminary results were reviewed,
and additional searches were conducted by
linking these primary keywords with ‘‘AND’’
and ‘‘OR’’ statements to the following secondary
keywords: ‘‘accelerometer,’’ ‘‘wrist actigraphy,’’
‘‘smartwatch,’’ ‘‘transducer,’’ ‘‘vibration,’’ ‘‘brain
mapping,’’ ‘‘magnetic resonance imaging,’’ and
‘‘positron emission tomography.’’ These sec-
ondary keywords were selected to narrow results
to objective methods rather than subjective
instruments like scales or questionnaires. When
applicable, corresponding Medical Subject
Headings (MeSH) were used. Only articles writ-
ten in English were included, and no restric-
tions were set on study type. To focus on
emerging methods, prioritization was given to
results from the last decade (2009–2019). This
review is based on previously conducted studies
and does not contain any studies with human
participants or animals performed by any of the
authors.
RESULTS
The search yielded 49 results in PubMed, 134
results in Embase, and 85 results in Web of
Science. Each result was independently
reviewed in a standardized manner by two of
the authors (M.S., K.L.), and disagreements
between reviewers were resolved by consensus.
Relevant findings were categorized into the
sections that follow, and a summary of these
results is presented in Table 1.
Video Surveillance
Video surveillance is not a new method to assess
pruritus in AD, but it is essential to include in
this review for two reasons. First, direct obser-
vation is considered the gold standard to
measure scratching as a proxy for itch. This
involves a trainer evaluator watching patients
while they sleep and recording the frequency
and duration scratching activity in real time
[16, 17]. Second, technological advances have
made it possible to observe scratching via video
surveillance by providing recorded footage that
can be reviewed at any time and by multiple
evaluators.
In recent years, several advancements have
further improved this method of pruritus
assessment, making it more efficient and accu-
rate. Video surveillance is almost exclusively
used to measure nocturnal itch, when the sub-
ject has limited activity. A potential challenge
of observing scratching behaviors during sleep
is that people are generally under covers that
can obscure the camera’s view. To address this,
infrared video cameras have been employed to
capture movements without disturbing sleep
[18]. Furthermore, researchers have developed
standardized criteria to evaluate recordings. For
example, ‘‘scratching bouts’’ are typically
defined as ‘‘an apparent action of rubbing or
scratching to any part of the body with a
rhythmical movement using hands, fingers, or
feet lasting longer than 5 s’’ [19]. By applying
this criteria, recordings can be analyzed by
multiple people, allowing for a comparison of
any difference, and ultimately a determination
of a quantitative value for itch. This method is
useful in that it offers an objective index of
overall scratch activity while simultaneously
tracking scratching at specific times and loca-
tions [18].
Despite the advantages of video surveillance,
it is a time-consuming endeavor, and patients
often decline this method because of privacy
concerns [19]. Furthermore, it is possible that
the placement of the recording device and/or
the patient’s body could result in ‘‘blind spots’’
where scratching behavior is hidden and
therefore not counted (e.g., a person sleeping
prone with a scratching hand wedged between
their abdomen and the mattress). Another lim-
itation is that patients’ awareness of being
recorded may alter their normal sleeping
behavior, such as reducing the depth or dura-
tion of sleep or other conscious or unconscious
modifications due to the observation. To
Dermatol Ther (Heidelb) (2019) 9:407–420 409
T
ab
le
1
Su
m
m
ar
y
of
em
er
gi
ng
m
et
ho
ds
to
ob
je
ct
iv
el
y
as
se
ss
pr
ur
it
us
in
at
op
ic
de
rm
at
it
is
M
et
ho
d
D
es
cr
ip
ti
on
A
dv
an
ta
ge
s
D
is
ad
va
nt
ag
es
Fu
tu
re
di
re
ct
io
ns
V
al
id
at
io
n
st
ud
ie
s
V
id
eo
su
rv
ei
lla
nc
e
V
id
eo
re
co
rd
in
g
de
vi
ce
w
it
h
in
fr
ar
ed
fil
te
r
is
ai
m
ed
at
pe
rs
on
’s
be
d
an
d
re
co
rd
s
fo
r
en
ti
re
du
ra
ti
on
of
sle
ep
;
re
co
rd
in
gs
ar
e
re
vi
ew
ed
by
ev
al
ua
to
r
w
ho
is
tr
ai
ne
d
to
re
co
rd
sc
ra
tc
hi
ng
ac
ti
vi
ty
D
ir
ec
t
ob
se
rv
at
io
n
is
th
e
go
ld
st
an
da
rd
to
m
ea
su
re
it
ch
C
ap
tu
re
it
ch
w
it
ho
ut
di
st
ur
bi
ng
sle
ep
St
an
da
rd
iz
ed
cr
it
er
ia
to
qu
an
ti
fy
it
ch
C
an
id
en
ti
fy
sp
ec
ifi
c
ar
ea
s
of
it
ch
L
im
it
ed
to
m
ea
su
re
no
ct
ur
na
l
it
ch
on
ly
Po
te
nt
ia
l
to
m
is
s
hi
dd
en
sc
ra
tc
hi
ng
(i
.e
.,
‘‘b
lin
d
sp
ot
s’’
)
Pr
iv
ac
y
co
nc
er
ns
of
vi
de
o
su
rv
ei
lli
ng
sle
ep
in
g
pa
ti
en
ts
H
ou
rs
of
re
vi
ew
in
g
su
rv
ei
lla
nc
e
fo
ot
ag
e
M
ac
hi
ne
le
ar
ni
ng
to
au
to
m
at
e
an
al
ys
is
do
ne
by
ev
al
ua
to
rs
E
ba
ta
et
al
.[
18
,1
9]
A
co
us
ti
c
su
rv
ei
lla
nc
e
So
un
d
de
te
ct
io
n
to
re
co
gn
iz
e
ac
ou
st
ic
si
gn
al
s
of
it
ch
O
nl
y
ta
ke
s
se
ve
ra
l
m
in
ut
es
fo
r
so
ft
w
ar
e
to
an
al
yz
e
so
un
d
da
ta
M
it
ig
at
es
pr
iv
ac
y
is
su
es
si
nc
e
no
vi
su
al
re
co
rd
in
g
an
d
no
hu
m
an
ob
se
rv
at
io
n
H
ig
hl
y
se
ns
it
iv
e
de
vi
ce
ca
n
ca
pt
ur
e
hi
dd
en
sc
ra
tc
hi
ng
L
im
it
ed
to
m
ea
su
re
no
ct
ur
na
l
it
ch
on
ly
L
im
it
ed
va
lid
at
io
n
da
ta
(o
ne
sm
al
l
st
ud
y
w
it
h
on
e
ni
gh
t
of
da
ta
)
L
ar
ge
r,
lo
ng
er
-t
er
m
st
ud
ie
s
to
va
lid
at
e
th
is
m
et
ho
d
U
m
ed
a
et
al
.[
21
];
N
or
o
et
al
.[
22
]
410 Dermatol Ther (Heidelb) (2019) 9:407–420
T
a
b
le
1
co
nt
in
ue
d
M
et
ho
d
D
es
cr
ip
ti
on
A
dv
an
ta
ge
s
D
is
ad
va
nt
ag
es
Fu
tu
re
di
re
ct
io
ns
V
al
id
at
io
n
st
ud
ie
s
W
ri
st
ac
ti
gr
ap
hy
A
po
rt
ab
le
de
vi
ce
th
at
us
es
a
m
ic
ro
ac
ce
le
ra
to
r
to
m
ea
su
re
w
ri
st
m
ov
em
en
t
as
a
pr
ox
y
fo
r
sc
ra
tc
hi
ng
ac
ti
vi
ty
A
ct
ig
ra
ph
s
ar
e
m
or
e
ac
cu
ra
te
,p
re
ci
se
,a
nd
re
lia
bl
e
th
an
ea
rl
ie
r
fo
rm
s
of
th
is
de
vi
ce
M
od
er
n
ve
rs
io
ns
ar
e
lig
ht
w
ei
gh
t
an
d
w
ir
el
es
s,
so
le
ss
in
te
rr
up
ti
ve
of
sle
ep
C
ap
tu
re
it
ch
ac
ti
vi
ty
in
re
al
ti
m
e
L
im
it
ed
to
m
ea
su
re
no
ct
ur
na
l
it
ch
on
ly
C
an
on
ly
ca
pt
ur
e
it
ch
in
g
th
at
in
vo
lv
es
w
ri
st
/a
rm
m
ov
em
en
t,
m
is
si
ng
ot
he
r
ac
ti
vi
ty
A
ct
ig
ra
ph
y
ha
s
be
en
fo
un
d
to
no
t
st
ro
ng
ly
co
rr
el
at
e
w
it
h
at
op
ic
de
rm
at
it
is
se
ve
ri
ty
N
ov
el
w
ay
s
to
be
tt
er
an
al
yz
e
ac
ti
gr
ap
hy
da
ta
(i
.e
.,
lo
gi
st
ic
re
gr
es
si
on
,c
lu
st
er
in
g
an
al
ys
is
)
B
id
ir
ec
ti
on
al
re
cu
rr
en
t
ne
ur
al
ne
tw
or
ks
to
be
tt
er
di
ff
er
en
ti
at
e
no
n-
sc
ra
tc
hi
ng
fr
om
sc
ra
tc
hi
ng
m
ot
io
n
B
ri
ng
hu
rs
t
et
al
.[
25
];
B
en
ja
m
in
et
al
.[
26
];
Fe
ue
rs
te
in
et
al
.[
28
];
W
oo
tt
on
et
al
.[
29
];
Pe
te
rs
en
et
al
.[
30
];
M
or
ea
u
et
al
.[
16
]
Sm
ar
t
de
vi
ce
s
C
om
bi
na
ti
on
of
sm
ar
tw
at
ch
w
it
h
a
hi
gh
ly
se
ns
it
iv
e
ac
ce
le
ro
m
et
er
th
at
co
nn
ec
ts
to
a
sm
ar
tp
ho
ne
th
at
re
co
rd
s
sc
ra
tc
hi
ng
ac
ti
vi
ty
an
d
ot
he
r
da
ta
H
ig
hl
y
se
ns
it
iv
e
ac
ce
le
ro
m
et
er
an
d
al
go
ri
th
m
s
ar
e
ab
le
to
di
sc
ri
m
in
at
e
sc
ra
tc
h
w
it
h
hi
gh
ac
cu
ra
cy
C
om
bi
ne
s
ob
je
ct
iv
e
da
ta
fr
om
sm
ar
tw
at
ch
w
it
h
su
bj
ec
ti
ve
da
ta
fr
om
sm
ar
tp
ho
ne
(i
.e
.,
pa
ti
en
t-
re
po
rt
ed
su
rv
ey
s)
C
ur
re
nt
ly
lim
it
ed
to
m
ea
su
re
no
ct
ur
na
l
it
ch
on
ly
Sm
ar
t
de
vi
ce
s
m
ay
be
to
o
ex
pe
ns
iv
e
in
ce
rt
ai
n
re
se
ar
ch
or
cl
in
ic
al
se
tt
in
gs
M
et
ho
d
ha
s
on
ly
be
en
va
lid
at
ed
in
ve
ry
lim
it
ed
pa
ti
en
t
po
pu
la
ti
on
s
Po
te
nt
ia
l
up
gr
ad
es
m
ay
al
lo
w
fo
r
sa
m
e
te
ch
no
lo
gy
to
ca
pt
ur
e
da
yt
im
e
sc
ra
tc
hi
ng
A
s
ne
w
ve
rs
io
ns
of
sm
ar
t
de
vi
ce
s
ar
e
re
le
as
ed
,c
os
ts
of
th
is
m
et
ho
d
fo
r
re
se
ar
ch
an
d
cl
in
ic
al
us
e
m
ay
de
cr
ea
se
Ik
om
a
et
al
.[
34
]
Dermatol Ther (Heidelb) (2019) 9:407–420 411
T
a
b
le
1
co
nt
in
ue
d
M
et
ho
d
D
es
cr
ip
ti
on
A
dv
an
ta
ge
s
D
is
ad
va
nt
ag
es
Fu
tu
re
di
re
ct
io
ns
V
al
id
at
io
n
st
ud
ie
s
V
ib
ra
ti
on
tr
an
sd
uc
er
s
A
sh
ee
t-
sh
ap
ed
pr
es
su
re
se
ns
or
lo
ca
te
d
un
de
r
a
m
at
tr
es
s
th
at
co
nt
in
uo
us
ly
re
co
rd
s
an
y
m
ov
em
en
t
or
ac
ti
vi
ty
Fo
un
d
to
de
te
ct
sle
ep
ve
rs
us
w
ak
e
st
at
es
w
it
h
al
m
os
t
id
en
ti
ca
l
ac
cu
ra
cy
to
w
ri
st
ac
ti
gr
ap
hy
M
os
t
us
ef
ul
to
ev
al
ua
te
ov
er
al
l
am
ou
nt
of
m
ot
io
n
du
ri
ng
sle
ep
N
ot
hi
gh
ly
se
ns
it
iv
e
or
sp
ec
ifi
c
fo
r
ca
pt
ur
in
g
sc
ra
tc
h-
sp
ec
ifi
c
m
ov
em
en
t
Po
te
nt
ia
l
fo
r
pa
ti
en
t
di
sc
om
fo
rt
,p
hy
si
ca
lly
or
w
it
h
re
sp
ec
t
to
pr
iv
ac
y
C
om
bi
ne
vi
br
at
io
n
tr
an
sd
uc
er
da
ta
w
it
h
vi
de
o
su
rv
ei
lla
nc
e
an
d
po
ly
so
m
no
gr
ap
hy
fo
r
a
m
or
e
co
m
pl
et
e
an
al
ys
is
of
ho
w
sle
ep
is
di
sr
up
te
d
by
it
ch
K
og
ur
e
et
al
.[
39
,4
0]
N
eu
ro
lo
gi
ca
l
im
ag
in
g
Fu
nc
ti
on
al
m
ag
ne
ti
c
re
so
na
nc
e
im
ag
in
g
(f
M
R
I)
or
po
si
tr
on
em
is
si
on
to
m
og
ra
ph
y
(P
E
T
)
to
as
se
ss
br
ai
n
an
at
om
y
an
d
ac
ti
vi
ty
in
pa
ti
en
ts
w
it
h
it
ch
C
an
be
us
ed
to
tr
ac
k
ch
an
ge
s
in
br
ai
n
ac
ti
vi
ty
du
ri
ng
ac
ut
e
ep
is
od
es
of
it
ch
,
in
cl
ud
in
g
w
he
n
a
pa
ti
en
t
is
aw
ak
e
Id
en
ti
fy
di
ff
er
en
ce
s
in
br
ai
n
an
at
om
y
in
st
at
es
of
ch
ro
ni
c
it
ch
V
al
id
at
io
n
st
ud
ie
s
in
sm
al
l
sa
m
pl
e
si
ze
s
w
it
h
va
ry
in
g
re
su
lts
M
et
ho
ds
lik
e
fM
R
I
an
d
PE
T
re
m
ai
n
to
o
ex
pe
ns
iv
e
fo
r
ro
ut
in
e
di
ag
no
st
ic
s
an
d
m
ig
ht
no
t
be
pr
ac
ti
ca
l
in
a
cl
in
ic
al
se
tt
in
g
In
it
ia
l
fin
di
ng
s
ar
e
gu
id
in
g
re
se
ar
ch
in
to
ne
w
tr
ea
tm
en
ts
fo
r
it
ch
(e
.g
.,
no
n-
in
va
si
ve
br
ai
n
st
im
ul
at
io
n)
E
xp
an
di
ng
up
on
th
is
w
or
k
to
ex
pl
or
e
th
e
ro
le
of
pe
ri
ph
er
al
ne
ur
on
s
in
th
e
sk
in
Sc
hn
ei
de
r
et
al
.[
42
];
Is
hi
uj
i
et
al
.[
43
];
Pa
po
iu
et
al
.[
44
];
M
oc
hi
zu
ki
et
al
.
[4
5,
46
]
412 Dermatol Ther (Heidelb) (2019) 9:407–420
mitigate these issues, new tools are under
development that offer less intrusive but more
comprehensive and automated methods of
visual scratching observation. One key area of
development is combining infrared video
recordings with machine-learning technologies
that can be programmed to ‘‘learn’’ scratching
movements [20], including unique movements
of an individual person. In this way, a machine
can take the place of a human observer, offering
the benefits of decreased variations in evaluator
judgement or visual fatigue, providing more
objective and consistent measurements across
patients. Such devices could offer a type of
personalized medicine for patients with AD by
evaluating their pruritus at baseline and in
response to different interventions.
Acoustic Surveillance
Given the many disadvantages of video
surveillance for measuring pruritus in AD, a
similar but alternative method has emerged:
acoustic surveillance. This method was first
tested in an AD mouse model (interleukin-18
transgenic mice) whereby scratching behavior
of these mice was captured using a sound
recording device [21]. The scratching sounds,
including frequency and wavelength informa-
tion, were analyzed to develop a software pro-
gram that could recognize and quantify the
mice’s scratching behavior, similar to video
surveillance but with no direct visualization and
with automated and thus much faster rates of
scratch data analysis. In this mouse model,
results from the acoustic counting system were
compared to video surveillance and found to be
identical [21].
Building upon this promising mouse model,
Noro et al. developed a sound detector with
similar acoustic surveillance technology but
designed to be worn on the wrist of humans and
capture their scratching behavior [22]. Very
interestingly, this device did not rely on air-
conducted noises but rather detected the
specific bone-conducted sound made by
scratching movements through the finger and
wrist bones [22]. To test this novel device,
sound data were gathered from healthy controls
and patients with AD while both groups slept
over one 6-h period. The subjects’ scratching
behavior was simultaneously observed by
infrared video. The software took a few minutes
to analyze the acoustic data compared to several
hours of a human observer scoring video
recordings. Ultimately, the authors reported
that the scratching time captured by the sound
detector was nearly identical to results from
video surveillance, the gold standard compar-
ison [22]. Thus, the sound detector eliminated
the intrusive need for visualization of human
behavior while also rapidly increasing the speed
and objectivity of analysis. As with video
surveillance, efforts are underway to optimize
acoustic surveillance with machine-learning
algorithms that analyze sound signals to rec-
ognize movement and quantify scratching
activity [23].
While acoustic recording does offer many
advantages over video surveillance, this device
has only been tested in one small, brief trial as
described above. Additional larger, longer-term
studies are needed to fully validate this method
in a wider variety of patient populations.
Wrist Actigraphy
A wrist actigraph is a portable device that uses a
microaccelerator to measure nocturnal wrist
movement as a proxy for scratching activity
that is correlated to itch in patients with AD
[17]. Movement data is collected in two to three
planes, stored locally in the device, and seam-
lessly uploaded for analysis. Although wrist
actigraphy has been used for decades [24, 25]
recent advancements have improved this tech-
nology to be more accurate, precise, and reliable
for clinical and research use. Devices are now
much smaller and less invasive (e.g., light-
weight and wireless), allowing them to be easily
used at home with minimal discomfort for the
user. In addition, wrist actigraphs are less
expensive than before, making this a more
affordable options for clinicians and research-
ers. Furthermore, wrist actigraphy is increas-
ingly being coupled to new methods of analysis
to improve usability and accuracy.
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Several studies have reported a strong corre-
lation between wrist actigraphy findings and
AD disease activity. Studies by Ebata et al. [24]
and Benjamin et al. [26] found a high correla-
tion between pruritus scoring from wrist acti-
graphs and infrared video recordings. However,
both studies noted that although wrist acti-
graphs are sensitive, increased specificity is
needed to distinguish nocturnal scratching
from other nocturnal movements. A study by
Hon et al. [27] evaluated children with AD and
determined that wrist actigraphy strongly cor-
related with disease severity as captured by
SCORing Atopic Dermatitis (SCORAD), an
instrument that combines objective compo-
nents of AD (i.e., clinician-assessed signs of
pruritus, such as excoriation) with subjective
symptoms (i.e., patient-reported itch severity
using a visual analogue scale). In this study,
wrist activities were correlated with both
objective SCORAD components and overall
SCORAD values among 24 pediatric patients
[27]. Such results support the use of wrist
actigraphy as an objective approach to measure
pruritus in adult and pediatric AD patient
populations.
Despite these advantages, there are several
limitations on the use of wrist actigraphy to
measure itch. First, wrist actigraphy can only be
used to measure nocturnal pruritus, since wrist
movement during the day could be due to any
number of activities that would be difficult to
discriminate from AD-related scratching [28].
Second, actigraphy generally captures itching
that involves wrist or arm movement, but
depending on placement of the device, it might
not record itching with the palm, feet, or slight
movements of individual fingers [16]. Further-
more, many patients with AD have developed
scratching techniques that involve rubbing
their torso or extremities against each other or a
part of their bed, which is unlikely to be
detected by a device on the wrist. Third, wrist
actigraphs are typically placed on the dominant
hand only, so any scratching activity from the
non-dominant hand would be missed. Fourth,
wrists are a very common site for AD involve-
ment, which is unfortunate since wearing an
actigraph could potentially cause further irrita-
tion to an area of the body already primed for
inflammation. A fifth and largely technical
point, several studies have validated the use of
wrist actigraphy to measure itch in AD, but
other results have challenged it. Most notably, a
large, multicenter randomized controlled trial
among children with AD failed to find a corre-
lation between wrist actigraphy and disease
severity or quality of life [29]. This study also
found that wrist actigraphy was not responsive
to change, an assessment of how an instrument
captures changes in disease status, which would
limit its utility in randomized controlled trials
and other research [29].
Fortunately, new techniques are being
developed to minimize these limitations and
optimize wrist actigraphy data for pruritus
assessment. Feuerstein et al. evaluated wrist
actigraphy data with a clustering analysis
designed to differentiate scratching from walk-
ing and restless sleep [28]. By including features
such as peak frequency and force of move-
ments, the cluster analysis exhibited a high
specificity and sensitivity for differentiating
walking from restless sleep, demonstrating its
ability to distinguish true scratching from other
activities [28]. These results were extended by
Petersen et al. who incorporated movement
features as independent variables in a logistic
regression (LR) [30]. This model similarly
demonstrated high discriminative ability to
separate scratch from other routine movements
[30]. Building on this work, Moreau et al.
described a two-step approach using high-reso-
lution, three-dimensional wrist actigraphy data:
(1) segmenting the data into ‘‘no motion,’’
‘‘single handed motion,’’ and ‘‘both handed
motion,’’ and then (2) discriminating motion
segments into scratching and other motion
using a bidirectional recurrent neural network
(RNN), a type of artificial intelligence that can
model dynamic, temporal behavior such as
scratching [16]. Results from this approach were
compared to infrared video scoring of pruritus
among 24 subjects (18 patients with AD and six
healthy controls) and demonstrated similar
results [16]. The authors also compared their
results to the LR by Petersen et al. described
above and concluded that the RNN algorithm
provided a better estimation of the total
amount of scratching and, perhaps more
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importantly, accurately predicted when
scratching occurred [16, 30]. Moreau et al.
noted that such capability could be helpful in
assessing the effectiveness of a treatment over
the course of a night, which is useful data for
clinicians managing itch as well as researchers
studying medication dosing [16].
Overall, improvements in the devices them-
selves and the methods used to analyze the
generated data have allowed wrist actigraphy to
re-emerge and continuously be improved as a
method to assess pruritus in AD. Nevertheless,
such methods still must be tested in larger
patient populations and directly compared to
other tools in large and diverse patient popula-
tions in order to be fully validated and suit-
able for clinical or research use.
Smart Devices
In the last decade, the medical community has
leveraged the convenience and computing
power of smart devices to learn more about
various medical conditions and also deliver
novel interventions, such as dietary intake
tracking and medication adherence reminders
[31, 32]. Pruritus researchers have joined this
technological revolution by leveraging the
fundamental principles of wrist actigraphy but
modernizing it into a smartwatch. In 2015, Lee
et al. reported a pilot study in which three
subjects wore a smartwatch with an accelerom-
eter to detect scratching. The smartwatch was
able to identify scratching behaviors with
98.5–99.0% accuracy for right-hand scratching
motion and 93.3–97.6% accuracy for left-hand
scratching when compared to infrared video
surveillance [33].
In 2017, a product named Itch Tracker was
developed through a partnership between der-
matologists, Nestle Skin Health, and Apple Inc.
Recognizing the need to have better objective
methods to evaluate itch, this team developed a
software application (app) that can be installed
to broadly used smartwatches and used to
measure nocturnal scratching. The app incor-
porates an algorithm that analyzes acceleration
data from the smartwatch and differentiates
scratching from other types of movement on
the basis of characteristic wrist motion [34].
Furthermore, the app also has a smartphone
interface where the user can answer itch-related
questionnaires, allowing for subjective, patient-
reported data to be combined with the objec-
tive, smartwatch-detected data.
Itch Tracker was validated in two proof-of-
concept studies, which included a total of 25
patients with AD and 10 healthy controls who
were simultaneously evaluated with the app
and nocturnal video surveillance. In the first
study, the investigators found that there was a
statistically significant positive correlation
between smartwatch-detected and video-cap-
tured scratching time per hour, and the second
study demonstrated that total scratching dura-
tion in AD patients was significantly longer
than in healthy controls and correlated posi-
tively with Eczema Area and Severity Index
(EASI) scores [35]. The team concluded that the
Itch Tracker had high validity and reliability in
measuring scratching in AD and conducted a
third, larger study with 201 people with similar
findings [34]. On the basis of these data, Itch
Tracker represents a smart device that can be
used to measure scratching and indirectly, but
objectively, evaluate the intensity of pruritus
among patients with AD. Owing to the simple
interface and unobtrusive design of Itch
Tracker, it is suitable for widespread use, but
further research will be required to validate the
app in more diverse patient populations and
clinical settings [34].
Vibration Transducers
Measurement of vibration is another method
that is not entirely new but has been updated by
modern technologies. In fact, one of the earliest
devices to measure itch was called a prurito-
meter [36]. It consisted of a resistive sensor and
amplifier glued to the middle finger of the
dominant hand. Fingernail vibration from
scratching would induce an electrical signal
transmitted to a wristwatch, providing data on
the frequency and intensity of scratching
[37, 38]. These devices had several limitations,
most notably the discomfort of placement in
such a conspicuous site and the high likelihood
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of the device being knocked askew or falling off
entirely, thus compromising any data
collection.
In recent years, less invasive and more
accurate ways to measure itch-related vibration
have been developed. In 2017, Kogure and
Ebata described the use of a sheet-shaped body
vibrometer (SBV) to measure sleep activity
among patients with AD [39]. The SBV consists
of a sensitive pressure sensor located under a
mattress that continuously records any move-
ment or activity [39]. These authors had previ-
ously reported the SBV detecting sleep versus
wake states with almost identical accuracy to
wrist actigraphy in a healthy population [40].
Expanding on this work, the authors compared
the SBV to wrist actigraphy in 20 patients with
AD and found the SBV to be most useful for
overall sleep evaluation in these patients (i.e.,
amount of motion during sleep) while wrist
actigraphy is better suited to specifically evalu-
ate scratching [39]. Therefore, the SBV may not
be the best option for measuring pruritus but it
is nonetheless another tool in the kit, especially
for evaluating the impact of AD on sleep
architecture among patients with severe itch.
Neurological Imaging
Neurological imaging has emerged as a partic-
ularly novel method to objectively detect
functional and anatomical changes in both
acute and chronic pruritus. For acute itch,
functional magnetic resonance imaging (fMRI)
or positron emission tomography (PET) has
been used to assess brain activity during exper-
imentally induced itching episodes [41]. In one
study, acute histamine-induced itch was com-
pared in eight patients with AD and six healthy
controls. PET scanning detected more cerebral
activation in patients with AD, including
increased activation of the basal ganglia that is
known to be a central mediator of the
itch–scratch cycle [42]. A similar study using
histamine induction with eight AD patients and
seven healthy controls utilized arterial spin
labeling fMRI and found similar results in terms
of significantly higher cerebral perfusion during
acute itch among AD patients [43]. In chronic
itch, brain imaging studies have shown that
scratching induces overactivity in motor-related
regions and the cerebral reward circuits. Fur-
thermore, in two studies using arterial spin
labeling fMRI to measure brain activity during
active scratching, patients with chronic itch
were found to have attenuated itch sensation in
response to scratching, in addition to signifi-
cant activation of cerebral structures involved
in the central reward system [44, 45]. Taken
together, these results demonstrate the plea-
surable aspects of scratching to relieve both
acute and chronic pruritus and suggest
scratching can be addictive for patients with
AD.
It is important to note three key limitations
of neurological imaging for acute and chronic
pruritus associated with AD [41]. First, most of
these studies represent small sample sizes and
results vary on the basis of itch induction and
imaging techniques. Second, no research has
been published demonstrating differences in
resting state between patients with AD and
healthy controls. Instead, these techniques
require an external itch stimulus (e.g., his-
tamine-induced) to demonstrate significant
differences that might not be exactly the same
as in AD-induced itch. Third, methods like fMRI
and PET take hours to perform and analyze and
are thus inconvenient for patients and quite
expensive to the health system. These consid-
erations make brain imaging less practical for
use in the clinical setting, especially for routine
diagnostics or standard of care.
Despite these limitations, the findings col-
lected from neurological imaging research
could help guide future studies towards devel-
oping new treatments, including psychological
interventions or non-invasive neurological
procedures like transcranial direct current
stimulation, which targets the pathways
involved in the itch–scratch cycle and can have
an antipruritic effect in AD [46]. An additional
advantage of brain imaging is that it can be used
to assess pruritus in AD patients while they are
awake, unlikely many of the previously descri-
bed methods that are limited to nocturnal
measurements. For these reasons, it is critical
that neurological imaging of pruritus is con-
tinued to better understand these pathways and
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identify potential targets to treat itch in AD
[47, 48].
CONCLUSIONS
The variety of new and improved methods to
evaluate pruritus in AD is welcomed by clini-
cians, researchers, and patients alike. While
many of these technologies are promising, no
single method discussed in this review can
capture the full spectrum of the effects of itch
on a patient’s quality of life, ranging from the
physical consequences like excoriation and
lichenification to the mental impacts that can
persist even in the absence of pruritus. It is
therefore imperative to continue developing
methods to quantify itch to accurately evaluate
individual patients, guide treatment, and
inform research on novel interventions to
reduce the symptoms and burdens of itch.
Future directions include next-generation smart
devices as well as exploring new territories, such
as identifying biomarkers that correlate to itch
and machine-learning programs to identify itch
processing in the brain. As these efforts con-
tinue, it will be essential to remain patient-
centered by developing techniques that mini-
mize discomfort, respect privacy, and provide
accurate data that can be used to better manage
itch in AD.
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